Idraparinux effective, but risky, for venous thromboembolism

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1606, 2007-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials

By Harenberg Job

European Journal of Clinical Pharmacology, Vol. 64, Iss. 6, 2008-06 ,pp. : 555-563

Springer Publishing Company

Access to resources Recommend Favorite

Idraparinux risky for embolism prevention in AF patients

Inpharma, Vol. 1, Iss. 1597, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Idraparinux sodium effective for DVT, but not PE

Inpharma, Vol. 1, Iss. 1570, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Proficient and Cost-Effective Approaches for the Prevention and Treatment of Venous Thrombosis and Thromboembolism

By Bick R.L.

Drugs, Vol. 60, Iss. 3, 2000-09 ,pp. : 575-595

Adis International

Access to resources Recommend Favorite

Tinzaparin in the treatment of venous thromboembolism

By Pineo Graham F Hull Russell D

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 12, 2003-12 ,pp. : 2355-2362

Informa Healthcare

Access to resources Recommend Favorite